Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First US Eliquis Generics Face Six-Year Wait

Mylan And Micro Labs Have Settled With BMS Over Apixaban

Executive Summary

Mylan and Micro Labs have received the first FDA approvals for generic rivals to BMS’ Eliquis oral anticoagulant. However, as a result of the firms’ settlements with the originator, BMS does not expect the generics to hit the US market until 2026.

You may also be interested in...



India Bars Four Firms On Apixaban

The High Court of Delhi has issued a temporary injunction blocking four Indian drug-makers from launching generic versions of Bristol-Myers’ top-selling anticoagulant apixaban.

Armas Launches Four US Injectables

Armas has kicked off 2020 with the launch of four generic injectables in the US.

Who’s Hired? Sandoz Germany Seeks A New Country Head

While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel